Halozyme Therapeutics Inc

24.08.2026 г., 23:36 ч. UTC

Halozyme Therapeutics Inc shares are lower in after-market hours. Broader market concerns over geopolitical tensions are impacting investor confidence.

21.08.2026 г., 19:36 ч. UTC

Halozyme Therapeutics Inc is trading higher, continuing its upward trend since Thursday's close. No specific news was identified to explain the movement.

20.08.2026 г., 20:06 ч. UTC

Halozyme Therapeutics shares are lower amid concerns over recent insider selling by CEO Helen Torley, who sold $2.13 million in stock.

19.08.2026 г., 19:56 ч. UTC

Halozyme Therapeutics shares are higher as investor confidence grows following the election of Dannielle Appelhans to its Board of Directors.

18.08.2026 г., 23:41 ч. UTC

Halozyme shares are lower in after-market trading following the announcement of Dannielle Appelhans' election to the Board of Directors, effective August 2026.

17.08.2026 г., 23:02 ч. UTC

Halozyme Therapeutics shares are higher in after-market hours, recovering from earlier session declines and remaining near the upper end of their one-month trading range.

14.08.2026 г., 20:06 ч. UTC

Halozyme Therapeutics Inc shares are lower amid broader market concerns following a decline in U.S. retail sales, continuing a trend of volatility.

13.08.2026 г., 19:56 ч. UTC

Halozyme Therapeutics Inc shares are lower during Thursday's session, having retraced from an earlier peak with no specific news to explain the decline.

12.08.2026 г., 19:16 ч. UTC

Halozyme Therapeutics Inc shares are lower, pressured by a high Relative Strength Index indicating potential overbought conditions amid recent market sentiment.

11.08.2026 г., 20:02 ч. UTC

Halozyme Therapeutics reported strong second-quarter earnings, raising full-year revenue guidance to $1.87 billion. Shares are trading roughly flat amid high trading volume.

10.08.2026 г., 22:36 ч. UTC

Halozyme Therapeutics shares are higher in after-market trading, reaching a high above the 20-day moving average and near the upper end of its one-month range.

7.08.2026 г., 23:21 ч. UTC

Halozyme Therapeutics reported strong Q2 earnings and raised guidance, yet shares are trading lower in after-market hours following notable weakness.

6.08.2026 г., 23:51 ч. UTC

Halozyme Therapeutics shares advanced in after-market trading following record second-quarter results, with revenue rising to $481 million and guidance increased for the year.

5.08.2026 г., 22:16 ч. UTC

Halozyme Therapeutics shares are lower in after-market trading, reflecting broader market pressures amid mixed sentiment from geopolitical developments and weak employment data.

4.08.2026 г., 19:22 ч. UTC

Halozyme Therapeutics is higher today, driven by 39.1% revenue growth from its ENHANZE technology, which enhances market share and earnings performance.

3.08.2026 г., 19:46 ч. UTC

Halozyme Therapeutics Inc. shares are lower today, despite earlier gains, amid a broader market rally following a significant drop in oil prices.

31.07.2026 г., 20:06 ч. UTC

Shares of Halozyme Therapeutics are lower today, reflecting broader market trends amid rising U.S. Treasury yields and crude oil prices influencing inflation concerns.

30.07.2026 г., 19:58 ч. UTC

Halozyme Therapeutics Inc shares are higher, reflecting a broader recovery in technology stocks amid improved market sentiment. The stock remains near its one-month range.

29.07.2026 г., 19:27 ч. UTC

Halozyme shares are higher today, despite earlier pulling back. Recent commentary raises concerns about future performance and potential writedowns from acquisitions.

28.07.2026 г., 20:03 ч. UTC

Halozyme Therapeutics Inc. is trading higher, benefiting from a broader upward trend in biotechnology stocks, despite a pullback earlier in the session.

27.07.2026 г., 19:46 ч. UTC

Shares of Halozyme Therapeutics Inc. are lower today, continuing a decline since Friday. Broader market sentiment is affected by a drop in crude oil prices.

24.07.2026 г., 20:07 ч. UTC

Halozyme Therapeutics is gaining traction as shares rise, supported by strong cash flow margins and revenue growth. The stock is currently priced at $80.60 per share.

22.07.2026 г., 19:35 ч. UTC

Halozyme Therapeutics shares are lower today, despite an earlier peak gain. The decline follows a drop since Tuesday's close amid rising crude oil prices.